Michael Torres Email & Phone Number

Successfully raised funds to launch CrossBridge in 2023. Built a top-tier team to develop our next-generation ADC technology.

Houston, TX, US

• Recruited and engaged with 15 high-impact cancer therapeutic projects andcompanies across the Texas ecosystem
• Developed a cancer therapeutic KOL advisor network
• Created a comprehensive curriculum and resource library for product development
• Promoted cohort companies to venture capital firms and secured VC participation in the accelerator program

Menlo Park, California & Durham, North Carolina, US

Menlo Park, California & Durham, North Carolina, US

• Corporate/Business Development Activities:
• Successfully transitioned an academic project into a full-formed VC-backed company. Raised $160M over two years led by Ecor1 and Pfizer Ventures with Orbimed, Colt Ventures, Vida Ventures, MPM, Osage University.
• Led the effort to secure a $3.2M Award from the CF Foundation. Direct lead quarterly meetings/deck preparations with the CF Foundation to provide program updates.
• Experienced in business development with external partners, led four strategic evaluations that resulted in a binding term sheet as part of ReCode 1.0. Supported planning efforts in strategy, competitive intelligence.
• Cultivated a deep network of sell-side, buy-side, and strategic contacts.
• Hands-on experience in patenting technology/working with university tech transfer offices tolicense the technology.

Menlo Park, California & Durham, North Carolina, US

Menlo Park, California & Durham, North Carolina, US

Prior responsibilities as Director of Biology included managing cross-functional teams to facilitate the preclinical development of our novel tRNA/mRNA LNP drug products. These key activities included designing and executing in vitro and in vivo pharmacology assays, DS and DP synthesis (CMC), bioanalytical methods to support PK and IND-enabling studies.

Dr. Michael J. Torres (PhD), (Senior Consultant) Dr. Torres has over 6 years of experience studying cancer biology under the mentorship of Michael White at UT-Southwestern Medical Center. He completed his PhD work in 2014. His work has resulted in several publications and has presented at various symposia. He currently is applying his efforts towards.

Actively perform due diligence and equity research in order to develop long and short thesis for short term and long term trades.Actively interact with members of the biotech trading community to discuss results, catalysts, management, and other aspects of understanding potential value of biotech companies.Ended 2013 with a portfolio percentage gain of 580%.

Dallas, Texas, US

Currently studying regulation of nonsense-mediated mRNA decay in the context of disease causing nonsense mutations in Cystic Fibrosis (nmCF), as well as characterizing novel putative NMD suppressors (natural products) as a therapeutic strategy for the treatment of nmCF.Areas of research: Cystic Fibrosis, Nonsense-mediated mRNA Decay Pathway, Compound.

Dallas, Texas, US

Completed dissertation research in the lab of Dr. Michael White.Used biochemical and genetic approaches to determine novel roles for proteins in cancer. Helped validate therapeutic target in collaboration with Amgen.Areas of Research: DNA-Damage Proteins, Pancreatic, Breast Cancer, Lung Cancer, and Signal Transduction.

Bethesda, MD, US

Applied and accepted into The National Institutes of Health (NIH) Undergraduate Scholarship Program (UGSP) which offers competitive scholarships to students from disadvantaged backgrounds who are committed to careers in biomedical, behavioral, and social science health-related research. The program offers:Scholarship supportPaid research training at the.

Doctor Of Philosophy (Ph.D.), Cancer Biology

Bs, Biology, General